Adrenal Adenoma 

  • Author: George T Griffing, MD; Chief Editor: George T Griffing, MD   more...
 
Updated: Sep 22, 2011
 

Background

Adrenal masses (AMs) are often discovered incidentally and are then termed adrenal incidentalomas (AIs). They are often discovered after an imaging procedure is performed that is unrelated to the adrenal gland. Usually, the patient has no signs of hormonal excess or obvious underlying malignancy. Incidence has been increasing proportionally to the use of radiographic imaging, as shown in the images below.[1] Less commonly, AMs are discovered as part of the clinical workup for suspected adrenal disease (eg, Cushing syndrome). (See Workup, as well as Clinical Presentation.)

Left adrenal mass discovered incidentally. Left adrenal mass discovered incidentally. Close-up of the left adrenal incidentaloma from thClose-up of the left adrenal incidentaloma from the above image.

The differential diagnosis of adrenal masses includes many primary, metastatic, benign, and malignant entities, most of which are not discussed at length here. (See Diagnosis )

Adrenal cortical adenoma is a common benign tumor arising from the cortex of the adrenal gland. It commonly occurs in adults, but it can be found in persons of any age. Adrenal cortical adenomas are not considered to have the potential for malignant transformation (see the images below).

Homogeneous, well-defined, 7-HU ovoid mass is seenHomogeneous, well-defined, 7-HU ovoid mass is seen in the right adrenal gland; this finding is diagnostic of a benign adrenal adenoma. Homogeneously enhancing ovoid mass is seen in the Homogeneously enhancing ovoid mass is seen in the left adrenal gland.

Because adrenal metastases may be found in as many as 25% of patients with known primary lesions, radiologists frequently face the task of determining whether an adrenal mass is benign or malignant. The question can directly affect the clinical management of the case. For instance, the workup for an otherwise resectable lung cancer may reveal the presence of an adrenal mass and suggest the possibility of metastatic disease. (See Workup.)

The treatment for a hormonally active (functional) adrenal tumor is surgery. The treatment for a malignancy depends on the cell type, spread, and location of the primary tumor.[2] Nonfunctional adrenal cortical adenomas are not premalignant, and surgical excision is not indicated. (See Treatment and Management.)

Much of the following discussion is on the clinical conundrum of the incidentally discovered AM. The term adrenal adenoma (AA) is used in the following discussion when nonadrenal sources occupying the adrenal area can be excluded. The term AM is used when a nonadrenal space-occupying structure cannot be excluded.

Next

Anatomy

The adrenal glands are located in the perirenal space near the upper pole of each kidney. Their appearance varies: they may be shaped like the letter H, L, Y, T, or V. Typically, they are less than 4 cm in length and less than 1 cm in width.

Previous
Next

Pathophysiology

The biochemical mechanisms depend on the underlying cell type. The cellular mechanisms for primary adrenocortical tumorigenesis are just beginning to be understood.

Previous
Next

Etiology

Some studies report an association with chromosomal and genetic abnormalities (genes coding for p53 and p57). Tumor markers are also present in other syndromes. The multiple endocrine neoplasia (MEN1) gene is linked to multiple endocrine neoplasia type 1. The aldosynthase/11-beta hydroxylase hybrid gene is associated with glucocorticoid-remediable hyperaldosteronism.

Another very rare cause of Cushing syndrome is adrenal-dependent macronodular hyperplasia associated with extremely large adrenal glands.

Previous
Next

Epidemiology

Adrenal masses (AMs) are a common finding on cross-sectional abdominal images. In about 1-5% of all cases, abdominal computed tomography (CT) scans that are obtained for reasons other than the evaluation for possible adrenal neoplasm demonstrate an AM; most of these are adrenal adenomas (AAs). The autopsy prevalence for AMs is 2-9% (see Table 1).

Table 1. Prevalence of AMs (Open Table in a new window)

Author Method Sample Size Prevalence, %
Russl (1941)Autopsy (>1 cm)131/90001.5
Kokko (1967)[3] Autopsy (>5 mm)21/14951.5
Hedeland (1967)Autopsy (>2 mm)64/7398.7
Glazer (1982)[4] CT scan16/22000.7
Abecassis (1985)[5] CT scan19/14591.3
Belldegrun (1986)[6] CT scan88/120000.7
Herrera (1991)[7] CT scan259/610540.4

Approximately 1-10% of CT scans and magnetic resonance images (MRIs) detect adrenal incidentalomas (AIs) that are 5 mm or larger. An Italian study of incidentally discovered AMs among subjects undergoing chest CT scan found that the prevalence of AAs was approximately 4%.[8]

The most important hormonally silent AA is pheochromocytoma. They are present in approximately 1 in 1000 autopsies. If the prevalence of AAs is 10-100 in 1000, then 1-10% of AIs are pheochromocytomas, as noted in the image below.

Adrenal incidentaloma and disease type. Adrenal incidentaloma and disease type.

Sex distribution for adrenal adenoma

Evidence suggests that the incidence in teenage girls is slightly higher than that of teenage boys, but no sex-related predilection is found in adults.

Age distribution for adrenal adenoma

Prevalence increases with age; the rate is less than 1% for patients younger than 30 years and is 7% for patients 70 years or older.

Previous
Next

Prognosis

Generally, the prognosis is excellent, but it depends on the type of underlying adrenal disease.

Approximately 80% of AAs are nonfunctional (hormonally silent) and benign. Twenty percent of AAs are either functional (hormonally active) or malignant and require further evaluation and treatment to avoid medical complications.

Patients with a previous history of cancer have a clinical course dictated by the primary tumor. Patients with adrenal cortical carcinomas have poor clinical outcomes, usually a 2- to 5-year 50% overall survival rate.

Pheochromocytomas may result in substantial complications, including death if not recognized. A 1981 series reported that less than one quarter of pheochromocytomas found post mortem were diagnosed ante mortem.[9] More than 90% of these patients had characteristic symptoms suggesting the unrecognized tumors were not silent. Many of the patients died of causes possibly related to the pheochromocytoma. Approximately 29% died unexpectedly during surgery, 27% died from cardiovascular causes, and 17% died from cerebrovascular causes.

Previous
Next

Patient Education

If pertinent, patients should know the signs and symptoms of adrenal insufficiency. Clinical clues include nausea, abdominal pain, fever, and diarrhea.

Previous
 
 
Contributor Information and Disclosures
Author

George T Griffing, MD  Professor of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physician Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical Research, Endocrine Society, International Society for Clinical Densitometry, and Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Coauthor(s)

Perry J Horwich, MD  Staff Physician, Instructor of Radiology, Department of Radiology, Beth Israel - Deaconess Medical Center

Perry J Horwich, MD is a member of the following medical societies: American College of Radiology, International Society for Magnetic Resonance in Medicine, and Radiological Society of North America

Disclosure: Nothing to disclose.

Stephen A Okon, MD  Consulting Staff, Assistant Professor of Radiology, Department of Radiology, Beth Israel Medical Center

Stephen A Okon, MD is a member of the following medical societies: American Medical Association and American Roentgen Ray Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Stanley Wallach, MD  Executive Director, American College of Nutrition; Clinical Professor, Department of Medicine, New York University School of Medicine

Stanley Wallach, MD is a member of the following medical societies: American College of Nutrition, American Society for Bone and Mineral Research, American Society for Clinical Investigation, American Society for Clinical Nutrition, American Society for Nutritional Sciences, Association of American Physicians, and Endocrine Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Don S Schalch, MD  Professor Emeritus, Department of Internal Medicine, Division of Endocrinology, University of Wisconsin Hospitals and Clinics

Don S Schalch, MD is a member of the following medical societies: American Diabetes Association, American Federation for Medical Research, Central Society for Clinical Research, and Endocrine Society

Disclosure: Nothing to disclose.

Mark Cooper, MBBS, PhD, FRACP  Head, Diabetes & Metabolism Division, Baker Heart Research Institute, Professor of Medicine, Monash University

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD  Professor of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physician Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical Research, Endocrine Society, International Society for Clinical Densitometry, and Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

References
  1. Terzolo M, Bovio S, Pia A, Reimondo G, Angeli A. Management of adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab. Apr 2009;23(2):233-43. [Medline].

  2. Yener S, Ertilav S, Secil M, Demir T, Akinci B, Kebapcilar L, et al. Prospective evaluation of tumor size and hormonal status in adrenal incidentalomas. J Endocrinol Invest. Jan 2010;33(1):32-6. [Medline].

  3. Kokko JP, Brown TC, Berman MM. Adrenal adenoma and hypertension. Lancet. Mar 4 1967;1(7488):468-70. [Medline].

  4. Glazer HS, Weyman PJ, Sagel SS, Levitt RG, McClennan BL. Nonfunctioning adrenal masses: incidental discovery on computed tomography. AJR Am J Roentgenol. Jul 1982;139(1):81-5. [Medline].

  5. Abecassis M, McLoughlin MJ, Langer B, Kudlow JE. Serendipitous adrenal masses: prevalence, significance, and management. Am J Surg. Jun 1985;149(6):783-8. [Medline].

  6. Belldegrun A, Hussain S, Seltzer SE, Loughlin KR, Gittes RF, Richie JP. Incidentally discovered mass of the adrenal gland. Surg Gynecol Obstet. Sep 1986;163(3):203-8. [Medline].

  7. Herrera MF, Grant CS, van Heerden JA, Sheedy PF, Ilstrup DM. Incidentally discovered adrenal tumors: an institutional perspective. Surgery. Dec 1991;110(6):1014-21. [Medline].

  8. Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. Apr 2006;29(4):298-302. [Medline].

  9. Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc. Jun 1981;56(6):354-60. [Medline].

  10. [Guideline] Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, et al. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract. Jul-Aug 2009;15 Suppl 1:1-20. [Medline]. [Full Text].

  11. Schmitz KJ, Helwig J, Bertram S, et al. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. J Clin Pathol. Jun 2011;64(6):529-35. [Medline]. [Full Text].

  12. Bin X, Qing Y, Linhui W, Li G, Yinghao S. Adrenal incidentalomas: Experience from a retrospective study in a Chinese population. Urol Oncol. May 29 2009;[Medline].

  13. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. Jul 1998;171(1):201-4. [Medline].

  14. Ho LM, Paulson EK, Brady MJ, Wong TZ, Schindera ST. Lipid-poor adenomas on unenhanced CT: does histogram analysis increase sensitivity compared with a mean attenuation threshold?. AJR Am J Roentgenol. Jul 2008;191(1):234-8. [Medline].

  15. Halefoglu AM, Bas N, Yasar A, Basak M. Differentiation of adrenal adenomas from nonadenomas using CT histogram analysis method: a prospective study. Eur J Radiol. Mar 2010;73(3):643-51. [Medline].

  16. Krestin GP, Steinbrich W, Friedmann G. Adrenal masses: evaluation with fast gradient-echo MR imaging and Gd-DTPA-enhanced dynamic studies. Radiology. Jun 1989;171(3):675-80. [Medline].

  17. Khati NJ, Javitt MC, Schwartz AM. Adrenal adenoma and hematoma mimicking a collision tumor at MR imaging. Radiographics. Jan-Feb 1999;19(1):235-9. [Medline].

  18. Yoh T, Hosono M, Komeya Y, Im SW, Ashikaga R, Shimono T, et al. Quantitative evaluation of norcholesterol scintigraphy, CT attenuation value, and chemical-shift MR imaging for characterizing adrenal adenomas. Ann Nucl Med. Jul 2008;22(6):513-9. [Medline].

  19. Korobkin M. CT characterization of adrenal masses: the time has come. Radiology. Dec 2000;217(3):629-32. [Medline].

  20. Liang HL, Pan HB, Lee YH, Huang JS, Wu TD, Chang CT, et al. Small functional adrenal cortical adenoma: treatment with CT-guided percutaneous acetic acid injection--report of three cases. Radiology. Nov 1999;213(2):612-5. [Medline].

  21. Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. Radiographics. Jul-Aug 2001;21(4):995-1012. [Medline].

  22. Otal P, Escourrou G, Mazerolles C, Janne d'Othee B, Mezghani S, Musso S, et al. Imaging features of uncommon adrenal masses with histopathologic correlation. Radiographics. May-Jun 1999;19(3):569-81. [Medline].

  23. Boland GW, Blake MA, Hahn PF, Mayo-Smith WW. Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization. Radiology. Dec 2008;249(3):756-75. [Medline].

  24. Muth A, Hammarstedt L, Hellstrom M, et al. Cohort study of patients with adrenal lesions discovered incidentally. Br J Surg. Oct 2011;98(10):1383-1391. [Medline].

  25. Mazzaglia PJ, Monchik JM. Limited value of adrenal biopsy in the evaluation of adrenal neoplasm: a decade of experience. Arch Surg. May 2009;144(5):465-70. [Medline].

  26. Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. J Clin Endocrinol Metab. Jul 2011;96(7):2004-15. [Medline].

  27. Leboulleux S, Deandreis D, Escourrou C, et al. Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy. Eur J Endocrinol. Jan 2011;164(1):89-94. [Medline].

Previous
Next
 
Characteristics of adrenal masses and their malignant potential.
Differential diagnosis of adrenal mass
Pituitary-adrenal axis and cortisol-secreting adrenal mass.
Adrenal incidentaloma and disease type.
Left adrenal mass discovered incidentally.
Close-up of the left adrenal incidentaloma from the above image.
Homogeneous, well-defined, 7-HU ovoid mass is seen in the right adrenal gland; this finding is diagnostic of a benign adrenal adenoma.
Homogeneously enhancing ovoid mass is seen in the left adrenal gland.
Table 1. Prevalence of AMs
Author Method Sample Size Prevalence, %
Russl (1941)Autopsy (>1 cm)131/90001.5
Kokko (1967)[3] Autopsy (>5 mm)21/14951.5
Hedeland (1967)Autopsy (>2 mm)64/7398.7
Glazer (1982)[4] CT scan16/22000.7
Abecassis (1985)[5] CT scan19/14591.3
Belldegrun (1986)[6] CT scan88/120000.7
Herrera (1991)[7] CT scan259/610540.4
Table 2. Evaluation of AM Syndromes
Diagnosis Features Biochemical Tests
PheochromocytomaHigh blood pressure, catechol symptomsUrine-free and plasma-free metanephrines
Primary aldosteronismHigh blood pressure, low K+, low PRA*Plasma aldosterone-to-renin ratio
Adrenocortical carcinomaVirilization or feminizationUrine 17-ketosteroids
Cushing or "silent" Cushing syndromeCushing symptoms or normal examination resultsOvernight 1-mg dexamethasone test
*Plasma renin activity
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.